Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report

Abstract Background In most patients, anemia is present when myelodysplastic syndrome is diagnosed. Although darbepoetin α is the first-choice supportive therapy for low-risk myelodysplastic syndrome, half of all patients develop a loss of response to darbepoetin α within 12 months. However, few rep...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Tatsuyoshi Ikenoue, Hiroshi Naito, Tetsuya Kitamura, Hideki Hattori
Médium: Artigo
Jazyk:Inglês
Vydáno: BMC 2017-10-01
Edice:Journal of Medical Case Reports
Témata:
Myelodysplastic syndromes
Anemia
Erythropoietin
Renal dialysis
On-line přístup:http://link.springer.com/article/10.1186/s13256-017-1468-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky